Related Experiment Video
Updated: Aug 6, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Normalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women
Dijana Hadziomerović1, Bernhard Rabenbauer, Ludwig Wildt
1Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Innsbruck, Innsbruck, Austria. dijanah@gmx.de
Objective:
Evaluation of the effects of naltrexone on hyperinsulinemia and hyperandrogenemia in hyperandrogenemic, hyperinsulinemic women.
Design:
Controlled clinical study.
Setting:
Department of Gynecologic Endocrinology and Reproductive Medicine, Center of Obstetrics and Gynecology, Medical University of Innsbruck, Austria.
Patient(S):
Thirty-nine hyperandrogenemic, hyperinsulinemic women were studied.
Intervention(S):
Women were treated with naltrexone (50 mg/d) for >or=3 weeks.
Main Outcome Measure(S):
Body mass index (BMI), gonadotropin (LH, FSH) and androgen (T, free T, DHEAS) levels, and plasma levels of glucose, insulin, and C-peptide, during a standard 75-g oral glucose tolerance test (OGTT), were determined before and during chronic opiate receptor blockade.
Result(S):
The BMI did not change during therapy. When OGTT was repeated after treatment with naltrexone, glucose levels were not different from those before treatment. Insulin response, however, had dramatically declined. We also observed a significant decrease in the levels of serum androgens.
Conclusion(S):
Hyperinsulinemia associated with hyperandrogenemia can be improved or completely abolished by chronic opiate receptor blockade. This observation suggests that endogenous opiates play a critical role in the process leading to hyperinsulinemia in hyperandrogenemia.
Related Concept Videos
Hypoglycemia and Glucagon
Hyperglycemia
Cushing Syndrome II: Pathophysiology
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Analgesia and Pain Management
Type II Diabetes II: Pathophysiology

